Greg Cima
Science and business reporter for 360Dx/GenomeWeb
Articles
-
2 weeks ago |
360dx.com | Greg Cima
NEW YORK – While hospitals and doctors' offices have mostly been using artificial intelligence-based tools for documentation and clerical tasks, experts in the space expect an incoming wave of applications for in-depth analysis of electronic health records, improved guidance on testing and treatment, and more efficient monitoring of care. In total, it could amount to a new future for the clinical use of AI.
-
2 weeks ago |
360dx.com | Greg Cima
NEW YORK – Backed by a better-than-expected $50 million fundraising round, Proscia plans to expand its commercial workforce by 30 percent over the next six months as the firm bolsters its lineup of artificial intelligence-developed clinical and research-use tools. David West, Proscia CEO, said that the investments will help the company to put its foot on the gas pedal to drive up commercial expansion.
-
1 month ago |
360dx.com | Greg Cima
NEW YORK – Sera Prognostics plans to support multiple studies starting this year to reinforce the evidence base for its blood test for the risk of preterm birth, the company said on Wednesday. It added that the results could be used to support commercial adoption of the test as well as inclusion in care guidelines and a potential submission for US Food and Drug Administration approval.
-
1 month ago |
360dx.com | Greg Cima
NEW YORK – With the US launch of its clinical-use digital pathology system, Epredia aims to win over labs with its high-throughput scanner, automated rescanning technology, and product menu that spans from slides to servers. The company recently announced that it had secured US Food and Drug Administration 510(k) clearance for its E1000 Dx Digital Pathology Solution, which is comprised of its whole-slide imaging scanner, slide image viewer, and image management and viewing software.
-
1 month ago |
360dx.com | Greg Cima
NEW YORK – BioAffinity Technologies said that it is cutting costs in its pathology lab and preparing to start a clinical trial for its sputum-based lung cancer test in a bid to expand into a national player in cancer diagnostics.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 72
- Tweets
- 149
- DMs Open
- Yes
RT @360DxNews: Meet Ravgen, the Little-Known Company Rattling NIPTs Biggest Players in Court. The firm alleges its competitors infringe its…
RT @360DxNews: UPDATE: FDA Allowed Problematic COVID-19 Tests on the Market Due to Agency's EUA Approach, HHS OIG Finds. In a report releas…
RT @360DxNews: Allergenis Seeks to Change Peanut Allergy Testing. Allergenis claims its assay results are more accurate than other first-li…